Our second COVID-19 impact survey of 4,500+ U.S. diabetes patients found ongoing drug/supply delays, care disruptions, and declines in diet and exercise.
Our quarterly U.S. diabetes survey found one-third of respondents had mild or severe depression, underscoring the need for more support and better treatments.
Our latest work examines the real-world psychosocial impact of Automated Insulin Delivery (AID) systems, analyzing user experiences, quality of life, and daily diabetes burden.
.png)
